Pliant Therapeutics, Inc. Stock Price, News & Analysis

Pliant Therapeutics (Nasdaq: PLRX) is presenting five posters at the ATS 2022 International Conference from May 13-18 in San Francisco. The posters showcase data supporting the development of PLN-74809, a dual-selective inhibitor for idiopathic pulmonary fibrosis (IPF). Key findings include dose-dependent target engagement and a favorable safety profile. Pliant is also featured in a special presentation during the ATS Respiratory Innovation Summit. PLN-74809 is currently in Phase 2 trials and has received Orphan Drug Designation from the FDA for IPF and primary sclerosing cholangitis.

Pliant Therapeutics (Nasdaq: PLRX), a clinical-stage biotechnology company, will have its CEO, Bernard Coulie, participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on April 12, 2022, at 2:15 p.m. ET. The event can be accessed via the Investor Relations’ Events & Presentation page on Pliant’s website, with an audio archive available for 30 days. Pliant focuses on developing therapies for fibrosis, with its lead candidate, PLN-74809, targeting idiopathic pulmonary fibrosis and primary sclerosing cholangitis, having received Orphan Drug Designation from the FDA.

Pliant Therapeutics, Inc. (Nasdaq: PLRX) recently corrected its financial reporting for 2021, highlighting significant advancements in its pipeline. The company reported a net loss of $24.5 million for Q4 2021, up from $19 million in the previous year. R&D expenses increased to $18.8 million, while G&A expenses rose to $7.8 million. PLN-74809, its lead therapeutic candidate, demonstrated robust biological activity in a Phase 1b trial and is poised for further trials in idiopathic pulmonary fibrosis and primary sclerosing cholangitis. The company has $200.6 million in cash, sufficient to fund operations into H2 2023.

Pliant Therapeutics (Nasdaq: PLRX) reported significant advancements in its pipeline in 2021, highlighted by promising Phase 1b trial results for PLN-74809, which demonstrated up to 92% inhibition of TGF-β activation in healthy subjects. The company is actively progressing into 2022 with a focus on idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC), including upcoming pivotal trials and regulatory developments. Financially, the company reported a net loss of $24.5 million in Q4 2021, an increase from the previous year, but maintains a robust cash position of $200.6 million to fund operations into mid-2023.

Pliant Therapeutics announced positive results from the expanded PLN-74809 Phase 1b trial, demonstrating significant TGF-β suppression in healthy participants, with reductions of up to 92% and 76% at 6 and 24 hours, respectively. The treatment was well tolerated, with no serious adverse events reported. This trial supports PLN-74809's potential as an antifibrotic therapy for idiopathic pulmonary fibrosis (IPF) and provides a favorable safety profile, contributing to de-risking ongoing Phase 2a trials.

Pliant Therapeutics (PLRX) announced the continuation of the INTEGRIS-IPF Phase 2a trial for PLN-74809, an oral treatment for idiopathic pulmonary fibrosis (IPF), without modifications following a positive recommendation from the Data Safety Monitoring Board (DSMB). The trial now progresses to evaluate a dosing increase to 320 mg daily over at least six months. PLN-74809 has demonstrated a favorable safety profile with over 450 participants showing no serious drug-related adverse events. Topline data is expected mid-2022.

Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology firm focused on fibrosis treatments, announced that Dr. Bernard Coulie will attend two upcoming conferences in March 2022. The first is the Cowen 42nd Annual Health Care Conference on March 8 at 2:10 p.m. ET, where he will join a respiratory/infections panel. The second is the Oppenheimer 32nd Annual Healthcare Conference on March 16 at 3:20 p.m. ET, where he will present a company update. Presentations can be accessed via the investor relations page of Pliant’s website.

Pliant Therapeutics (PLRX) announced the completion of enrollment in its INTEGRIS-IPF Phase 2a clinical trial, evaluating PLN-74809 in patients with idiopathic pulmonary fibrosis (IPF). The FDA has authorized long-term treatment evaluation of PLN-74809 at doses up to 320 mg. Topline data from the trial is expected mid-2022. The company plans to provide updates at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022. The trial involves 84 patients over a 12-week period, assessing safety and efficacy metrics.

Pliant Therapeutics, a clinical stage biotechnology firm focused on fibrosis treatments, announced that its CEO, Bernard Coulie, will present a company update at the 40th Annual J.P. Morgan Healthcare Conference.

The virtual presentation is scheduled for January 12, 2022, at 9:45 a.m. ET. Access is available via the Investor Relations' Events page on Pliant's website, with a replay option for 30 days post-event.

Pliant's lead candidate, PLN-74809, is in Phase 2a trials for idiopathic pulmonary fibrosis and primary sclerosing cholangitis.